Understand breast fibrocystic disease, also known as fibrocystic breast changes, fibrocystic mastopathy, or cystic mastopathy. Learn about diagnosis, symptoms, and treatment options. Find information on clinical documentation and medical coding for fibrocystic breast conditions. This resource provides healthcare professionals with relevant information on breast fibrocystic disease.
Also known as
Noninflammatory disorders of female breast
Covers fibrocystic changes and other benign breast conditions.
Inflammatory diseases of breast
Includes mastitis and other inflammatory breast problems, sometimes related to fibrocystic changes.
Abnormal findings on diagnostic imaging of breast
Includes abnormal mammogram or ultrasound results that may indicate fibrocystic disease.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the fibrocystic breast disease simple or specified type?
When to use each related code
| Description |
|---|
| Benign breast lumps, cysts, and pain. |
| Breast pain without lumps or other findings. |
| Single or multiple breast cysts, fluid-filled sacs. |
Incorrect coding between unspecified fibrocystic changes (N60.89) and solitary cyst (N60.10) based on documentation.
Missing or unclear documentation of laterality (right, left, bilateral) impacting code selection and reimbursement.
Overuse of unspecified codes (N60.89) when documentation supports more specific fibrocystic conditions.
Q: How can I differentiate between fibrocystic breast changes and breast cancer during a clinical breast exam?
A: Differentiating fibrocystic breast changes from breast cancer during a clinical breast exam can be challenging due to overlapping symptoms. Fibrocystic changes often present as multiple, mobile, tender, and often bilateral masses that fluctuate with the menstrual cycle. These masses are typically smooth and well-defined. Conversely, breast cancer usually presents as a single, firm, non-tender, fixed, and irregularly shaped mass, often with associated skin changes like dimpling or nipple retraction. While a thorough clinical breast exam is crucial, it's important to remember it's not a definitive diagnostic tool. If any suspicious findings are detected, further investigation with imaging studies like mammography or ultrasound, and potentially biopsy, is essential for accurate diagnosis. Consider implementing a standardized breast exam protocol and documentation process to ensure consistency and thoroughness in your practice. Explore how S10.AI can assist in documenting and tracking patient breast health data for improved clinical decision-making.
Q: What are the evidence-based management strategies for symptomatic fibrocystic mastopathy in premenopausal women?
A: Managing symptomatic fibrocystic mastopathy in premenopausal women focuses primarily on alleviating discomfort. Evidence-based strategies include lifestyle modifications such as wearing a supportive bra, limiting caffeine and salt intake, and potentially using over-the-counter pain relievers like ibuprofen or NSAIDs. While the evidence is less conclusive, some women find relief with evening primrose oil or vitamin E supplementation. It's crucial to discuss these options with patients, emphasizing that they may not work for everyone. For severe pain or persistent symptoms, hormonal therapies like oral contraceptives may be considered, but the potential risks and benefits should be carefully evaluated. Learn more about the latest research on managing fibrocystic breast changes and how S10.AI can help you stay updated on current best practices.
Patient presents with complaints consistent with fibrocystic breast changes, including breast pain, tenderness, and a sensation of lumpiness or thickening in the breast tissue. Symptoms may be cyclical, fluctuating with the menstrual cycle, and often exacerbated premenstrually. Physical examination reveals palpable nodularity, described as rope-like or granular, bilaterally. The patient denies any nipple discharge, skin changes, or family history of breast cancer. No palpable dominant masses are identified. Ultrasound of the breasts was performed to evaluate the areas of concern and revealed findings consistent with fibrocystic mastopathy, demonstrating multiple small cysts and areas of increased fibroglandular tissue. Mammography was considered but deferred due to the patient's age and the benign nature of the ultrasound findings. Diagnosis of fibrocystic breast disease was established based on clinical presentation, physical exam findings, and imaging results. Patient education was provided regarding the benign nature of this condition, emphasizing that fibrocystic changes are common and not associated with an increased risk of breast cancer. Conservative management was recommended, including supportive bra, over-the-counter pain relievers such as ibuprofen or acetaminophen, and lifestyle modifications such as reducing caffeine and salt intake. The patient was advised to perform regular breast self-exams and to return for follow-up if symptoms worsen or new changes develop. This documentation supports the medical necessity for the evaluation and management of cystic mastopathy, justifying CPT codes for the breast exam and ultrasound. ICD-10 code N60.10 is appropriate for this encounter.